Instem plc Directorate Change (2691N)
29 Septiembre 2021 - 1:00AM
UK Regulatory
TIDMINS
RNS Number : 2691N
Instem plc
29 September 2021
Instem plc
("Instem")
Appointment of Independent Non-Executive Director
Instem plc (AIM: INS), a leading provider of IT solutions to the
global life sciences market, announces that it has appointed Riaz
Bandali as an independent non-executive director to the Board
effective 1 December 2021. Riaz will also be appointed to the Audit
and Remuneration Committees.
Riaz has spent his entire career in the healthcare and life
sciences industries in a variety of strategic, commercial and
operational roles at senior level, also including exposure to
fundraising and M&A activity.
Riaz is currently CEO of Emerald Health Therapeutics, listed on
the Canadian Stock Exchange (CSE: EMH), a role he has held since
2019. Prior to that, Riaz was with Syneos Health for nine years,
firstly leading their Early Stage Contract Research Services
business then becoming Chief Innovation Officer and more recently
as President, Early Phase Development and Translational Sciences,
with responsibility for a team of 900 people globally.
He started his career in 1994 spending eight years at MDS
Capital Corp as a Venture Capital investor, as part of a a $1bn
Canadian Health & Life Sciences fund. In 2002, Riaz moved into
industry with MDS portfolio company MDS Sciex until 2006, when he
moved to MDS Pharma Services (now Celerion), a global clinical
pharmacology and bioanalysis business. Between 2008 and 2010, he
was Senior Vice President at AB Sciex and Molecular Devices (part
of Danaher), leading M&A and key growth strategies.
Since mid-2019 Riaz has also been a member of Instem's Client
Strategic Advisory Board ("SAB"), a non-remunerated role. This
position has provided Riaz with a unique understanding of Instem's
business whilst from an objective standpoint. The purpose of the
SAB, which meets several times p.a., is to provide third party
insight on Instem's business, product and service strategy from
both a customer and competitor perspective. Riaz has stepped down
from the SAB effective upon his appointment to Instem's Board of
Directors.
Mr Bandali holds a BSc in Microbiology from the University of
British Columbia and an MBA from McGill University. Mr Bandali has
also participated in Harvard Business School's Advanced Management
Programme.
Commenting on the appointment, David Gare, Non-executive
Chairman, said: " We are delighted to welcome Riaz to the Board of
Instem as an Independent Non-Executive Director ("NED"). Riaz
brings with him a wealth of relevant experience and contacts in the
North American and wider life sciences industry. He has a broad
familiarity with the technical nature of Instem's business as a
result of his time spent working in the directly related client
domain and on Instem's Client Strategic Advisory Board. This will
stand Riaz in good stead to add value to Instem in his new role. We
are also continuing with our efforts to identify a further suitable
Independent NED candidate and look forward to updating shareholders
in due course."
Further disclosures pursuant to Schedule Two, paragraph (g) of
the AIM Rules for Companies:
Riaz Amirali Bandali, age 52, is currently or has previously
been a director of the following companies within the past five
years:
Current Directorships Previous Directorships
Emerald Health Therapeutics Syneos Health Clinique, Inc.
Inc.
Inventiv Health Clinique, Inc.
Pure Sunfarms Corp.
Riaz has no beneficial interest in the equity securities of
Instem plc.
Save as disclosed above, there is no further information to be
disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules
for Companies.
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated
Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Rachel Hayes
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
Nicholas Johnson
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
ManagementRegulatory Submissions, Clinical Trial Acceleration, and
Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide,
including all the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug
development value chain, from discovery through to market launch.
Management estimate that over 50% of all drugs on the market have
been through some part of Instem's platform at some stage of their
development.
To learn more about Instem solutions and its mission, please visit www.instem.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUUUBUPGGAR
(END) Dow Jones Newswires
September 29, 2021 02:00 ET (06:00 GMT)
Instem (LSE:INS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Instem (LSE:INS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
